Jennis Singla*, Naglaa Ghobriel, Cynthia Chioma Anyakorah, Lea Bach-Bachich, Sammy Termanini, David R. Perkins, Julio Perez, Prem Kumar Sah, Syeda Hafsa Kazmi, nikitha Chellapuram, Amail Kasi, Rishubh Loei, Prabhnoor Kaur, Hebatalla Ismail, Tony Alarcon, Anand Reddy Maligireddy, Venkata Dayana


The Severe Acute Respiratory Syndrome Coronavirus Disease-2 (SARS-CoV-2) is the causative agent of coronavirus disease-19 (COVID-19). This outbreak has been declared a pandemic by the World Health Organization, and it has become a public health emergency of international concern. Most of the population is experiencing signs and symptoms similar to the flu and common cold. Despite that, alveolar destruction resulting in progressive lung failure has also been underlined. Although SARS-CoV-2 has been noted principally to affect the lungs, other system involvement has been described too. Hematological involvement has also been emphasized in the literature, including lymphopenia, anemia, cytopenia, and thrombocytopenia. The coagulation abnormalities and disseminated intravascular coagulation were observed in severe COVID-19 cases. This COVID-19 pandemic has also affected the hospital services, injured blood product supply, disturbed chemotherapy treatment, and hematopoietic stem cell transplantation program. Hematological and immune abnormalities are often encountered in critical illness and have prognostic significance. Careful monitoring of hematological constraints at the outset and disease course is useful for identifying patients at high risk of severe disease. Moreover, patients with pre-existing hematological disorders are at increased risk of severe infection. Patients with hematological involvement usually experience a wide range of signs and symptoms such as shortness of breath, headache, nausea, drowsiness, vomiting, tachycardia, and tachypnea. The pandemic of SARS-CoV-2 has become an unprecedented challenge for the physicians and the hematologists. This review has summarized the data from published literature to describe the disease's hematological manifestations, and its implication on patients' management observed in COVID-19 cases.

Keywords: SARS-CoV-2, COVID-19, hematology, anemia, thrombocytopenia, lypmphopenia.

[Full Text Article]


Forgot Password  |  Register


Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation


    FEBRUARY 2023 Issue has been successfully launched on 1 FEBRUARY 2023.

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.


UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS


Copyright From

Covering Letter

                        Author Instruction